Advertisement
UK markets open in 3 hours 10 minutes
  • NIKKEI 225

    38,689.22
    +92.75 (+0.24%)
     
  • HANG SENG

    17,843.34
    -185.18 (-1.03%)
     
  • CRUDE OIL

    80.64
    -0.09 (-0.11%)
     
  • GOLD FUTURES

    2,337.80
    +6.60 (+0.28%)
     
  • DOW

    39,150.33
    +15.53 (+0.04%)
     
  • Bitcoin GBP

    49,709.04
    -1,258.14 (-2.47%)
     
  • CMC Crypto 200

    1,297.10
    -63.23 (-4.64%)
     
  • NASDAQ Composite

    17,689.36
    -32.24 (-0.18%)
     
  • UK FTSE All Share

    4,490.92
    -17.52 (-0.39%)
     

Global Parkinson's Disease Treatment Market to Reach $8 Billion by 2030

ReportLinker
ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, May 16, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Parkinson’s Disease Treatment Industry" - https://www.reportlinker.com/p06032441/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Parkinson’s Disease Treatment Market to Reach $8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Parkinson’s Disease Treatment estimated at US$4.9 Billion in the year 2022, is projected to reach a revised size of US$8 Billion by 2030, growing at aCAGR of 6.4% over the period 2022-2030. Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record 8% CAGR and reach US$2.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dopamine Receptor Agonists segment is readjusted to a revised 5.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 10.2% CAGR

The Parkinson’s Disease Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Select Competitors (Total 42 Featured)
- AbbVie
- Acadia
- Boehringer Ingelheim
- Dr. Reddy’s
- GSK
- Impax
- Lundbeck
- Merck
- Novartis
- Sun Pharma
- Teva
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Wockhardt


Read the full report: https://www.reportlinker.com/p06032441/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Parkinson’s Disease Treatment - Global Key Competitors
Percentage Market Share in 2021 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2021 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Parkinson’s Disease
Treatment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Parkinson’s Disease
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2014,
2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Levodopa / Carbidopa by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Levodopa / Carbidopa by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for Levodopa / Carbidopa by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Dopamine Receptor Agonists by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Dopamine Receptor Agonists
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 9: World 16-Year Perspective for Dopamine Receptor
Agonists by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 10: World Recent Past, Current & Future Analysis for
MAO-Inhibitors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for MAO-Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 12: World 16-Year Perspective for MAO-Inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
COMT-inhibitors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for COMT-inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for COMT-inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Anticholinergics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Anticholinergics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Anticholinergics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Other Drug Classes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Other Drug Classes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Other Drug Classes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Hospitals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 24: World 16-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Clinics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 27: World 16-Year Perspective for Clinics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 28: World Parkinson’s Disease Treatment Market Analysis
of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2023
(E)
Table 29: USA Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 30: USA Historic Review for Parkinson’s Disease Treatment
by Drug Class - Levodopa / Carbidopa, Dopamine Receptor
Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and
Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 31: USA 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 32: USA Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 33: USA Historic Review for Parkinson’s Disease Treatment
by End-Use - Hospitals and Clinics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 34: USA 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 36: Canada Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 37: Canada 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 38: Canada Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 39: Canada Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 40: Canada 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

JAPAN
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 41: Japan Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: Japan Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 43: Japan 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 44: Japan Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 45: Japan Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 46: Japan 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

CHINA
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2023 (E)
Table 47: China Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 48: China Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 49: China 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 50: China Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 51: China Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 52: China 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

EUROPE
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 53: Europe Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 54: Europe Historic Review for Parkinson’s Disease
Treatment by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 55: Europe 16-Year Perspective for Parkinson’s Disease
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2014, 2023 & 2030

Table 56: Europe Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 57: Europe Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 58: Europe 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 60: Europe Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 61: Europe 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

FRANCE
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2023 (E)
Table 62: France Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 63: France Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 64: France 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 65: France Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 66: France Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 67: France 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

GERMANY
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 68: Germany Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 69: Germany Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 70: Germany 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 71: Germany Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 72: Germany Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 73: Germany 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

ITALY
Table 74: Italy Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 75: Italy Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 76: Italy 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 77: Italy Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 78: Italy Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 79: Italy 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

UNITED KINGDOM
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2023
(E)
Table 80: UK Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: UK Historic Review for Parkinson’s Disease Treatment
by Drug Class - Levodopa / Carbidopa, Dopamine Receptor
Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and
Other Drug Classes Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 82: UK 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 83: UK Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 84: UK Historic Review for Parkinson’s Disease Treatment
by End-Use - Hospitals and Clinics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 85: UK 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 87: Spain Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 88: Spain 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 89: Spain Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 90: Spain Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 91: Spain 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: Russia Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 94: Russia 16-Year Perspective for Parkinson’s Disease
Treatment by Drug Class - Percentage Breakdown of Value Sales
for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 95: Russia Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 96: Russia Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 97: Russia 16-Year Perspective for Parkinson’s Disease
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals and Clinics for the Years 2014, 2023 & 2030

REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 99: Rest of Europe Historic Review for Parkinson’s
Disease Treatment by Drug Class - Levodopa / Carbidopa,
Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 100: Rest of Europe 16-Year Perspective for Parkinson’s
Disease Treatment by Drug Class - Percentage Breakdown of Value
Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Parkinson’s Disease Treatment by End-Use -
Hospitals and Clinics - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Parkinson’s
Disease Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 103: Rest of Europe 16-Year Perspective for Parkinson’s
Disease Treatment by End-Use - Percentage Breakdown of Value
Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030

ASIA-PACIFIC
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Parkinson’s Disease Treatment by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 105: Asia-Pacific Historic Review for Parkinson’s Disease
Treatment by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 106: Asia-Pacific 16-Year Perspective for Parkinson’s
Disease Treatment by Geographic Region - Percentage Breakdown
of Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2014, 2023 & 2030

Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 108: Asia-Pacific Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 109: Asia-Pacific 16-Year Perspective for Parkinson’s
Disease Treatment by Drug Class - Percentage Breakdown of Value
Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 110: Asia-Pacific Recent Past, Current & Future Analysis
for Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 111: Asia-Pacific Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 112: Asia-Pacific 16-Year Perspective for Parkinson’s
Disease Treatment by End-Use - Percentage Breakdown of Value
Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030

AUSTRALIA
Parkinson’s Disease Treatment Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Australia for 2023 (E)
Table 113: Australia Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by Drug Class - Levodopa /
Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors,
COMT-inhibitors, Anticholinergics and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 114: Australia Historic Review for Parkinson’s Disease
Treatment by Drug Class - Levodopa / Carbidopa, Dopamine
Receptor Agonists, MAO-Inhibitors, COMT-inhibitors,
Anticholinergics and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 115: Australia 16-Year Perspective for Parkinson’s
Disease Treatment by Drug Class - Percentage Breakdown of Value
Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists,
MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 116: Australia Recent Past, Current & Future Analysis for
Parkinson’s Disease Treatment by End-Use - Hospitals and
Clinics - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 117: Australia Historic Review for Parkinson’s Disease
Treatment by End-Use - Hospitals and Clinics Markets -

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032441/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001